MaaT Pharma presented today, at the annual meeting of the American Society of Hematology (ASH), the world’s largest hematology meeting, promising consolidated results from 81 patients with acute Gastrointestinal (GI) graft-versus-host (aGvH) and steroid-resistant patients treated with MaaT013 under the compassionate access program (EAP) in France:
• Overall response rate (GI-ORR) of 56%, including 30 patients in complete response (37%), 11 patients in very good partial response (14%) and 4 patients in partial response (5%) in patients with of GI-aGvH 28 days after initiation of treatment;
• Overall survival rate at 12 months was 59% in patients responding to treatment with MaaT013.
• An overall response rate of 65% was observed in 31 patients treated with MaaT013 as 3rd line treatment in patients after failure of 2nd line treatment with ruxolitinib. In this group that responded to treatment with MaaT013, the 12-month survival rate was 74%. A similar patient population is currently receiving treatment in the pivotal Phase III ARES clinical trial being conducted by MaaT Pharma in Europe.
To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]